ReviewTrends in microbiology2010
Potential role for mucosally active vaccines against pneumococcal pneumonia.
Review in Trends in microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.Mucosal immunology · 2015Trial
- Integrated analysis of humoral and T-cell responses to pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients.Frontiers in medicine · 2026Article
- Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19.Journal of intensive medicine · 2024Review
- A broad-spectrum pneumococcal vaccine induces mucosal immunity and protects against lethalEmerging microbes & infections · 2023Article
- Outer membrane vesicles from bacteria: Role and potential value in the pathogenesis of chronic respiratory diseases.Frontiers in cellular and infection microbiology · 2022Review
- Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation.Frontiers in immunology · 2021Article
- Nasal Pneumococcal Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens.American journal of respiratory and critical care medicine · 2020Article
- Pneumococcal Vaccines.Microbiology spectrum · 2019Review
- Impact of different Streptococcus pneumoniae on the secretion of interleukin and adhesin from THP-1 monocytes.Journal of clinical laboratory analysis · 2019Article
- A novel extracellular vesicle-associated endodeoxyribonuclease helps Streptococcus pneumoniae evade neutrophil extracellular traps and is required for full virulence.Scientific reports · 2018Article
- Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.Infection and immunity · 2017Article
- Next generation protein based Streptococcus pneumoniae vaccines.Human vaccines & immunotherapeutics · 2016Review
- Differences in Homing Potentials of Streptococcus pneumoniae-Specific Plasmablasts in Pneumococcal Pneumonia and After Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccinations.The Journal of infectious diseases · 2015Article
- A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.Journal of virology · 2014Article
- Development ofVaccines · 2014Article
- Serotype-independent pneumococcal vaccines.Cellular and molecular life sciences : CMLS · 2013Review
- Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.American journal of respiratory and critical care medicine · 2013Article
- Inactivated pep27 mutant as an effective mucosal vaccine against a secondary lethal pneumococcal challenge in mice.Clinical and experimental vaccine research · 2013Article
- Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Pneumococcal pneumonia is a life-threatening disease with high mortality and morbidity among children under 5 years of age, the elderly and immunocompromised individuals worldwide. Protection against pneumococcal pneumonia relies on successful regulation of colonisation in the nasopharynx and a brisk alveolar macrophage-mediated immune response in the lung. Therefore, enhancing pulmonary mucosal immunity (which includes a combination of innate, humoral and cell-mediated immunity) through mucosal vaccination might be the key to prevention of pneumococcal infection. Current challenges include a lack of information in humans on mucosal immunity against pneumococci and a lack of suitable adjuvants for new vaccines. Data from mouse models, however, suggest that mucosally active vaccines will enhance mucosal and systemic immunity for protection against pneumococcal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.